Use of sugammadex in lung cancer patients undergoing video-assisted thoracoscopic lobectomy.
10.4097/kjae.2017.70.4.420
- Author:
Hyun Chul CHO
1
;
Jong Hwan LEE
;
Seung Cheol LEE
;
Sang Yoong PARK
;
Jong Cheol RIM
;
So Ron CHOI
Author Information
1. Department of Anesthesiology and Pain Medicine, Dong-A University Hospital, Busan, Korea. choisr@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Effect;
Sugammadex;
Thoracoscopic lobectomy;
VATS lobectomy
- MeSH:
Atropine;
Chest Tubes;
Glycopyrrolate;
Humans;
Incidence;
Length of Stay;
Lung Neoplasms*;
Lung*;
Medical Records;
Pneumonia;
Pulmonary Atelectasis;
Pyridostigmine Bromide;
Retrospective Studies;
Thoracic Surgery, Video-Assisted
- From:Korean Journal of Anesthesiology
2017;70(4):420-425
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This study aimed to retrospectively evaluate the use of sugammadex in patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy. METHODS: Data were obtained from medical record review of patients who underwent VATS lobectomy from January 2013 to November 2014. Fifty patients were divided into two groups: the sugammadex group (group S, n = 19) was administered sugammadex 2 mg/kg, while the pyridostigmine group (group P, n = 31) received pyridostigmine 20 mg with glycopyrrolate 0.2 mg or atropine 0.5 mg. The primary endpoint measure was the overall incidence of postoperative pulmonary complications including prolonged air leak, pneumonia, and atelectasis. The secondary endpoint measures were the length of postoperative hospital stay and duration of chest tube insertion. RESULTS: The overall incidence of postoperative pulmonary complications in patients in group S was significantly lower compared with that of group P (5 [26.3%] vs. 17 [54.8%]; P = 0.049). Also, the durations of chest tube insertion (5.0 [4.0–7.0] vs. 7.0 [6.0–8.0] days; P = 0.014) and postoperative hospital stay (8.0 [8.0–10.0] vs. 10.0 [9.0–11.0] days; P = 0.019) were shorter in group S compared with group P. Administration of sugammadex was associated reduced with postoperative pulmonary complications (OR: 0.22; 95% CI: 0.05–0.87; P = 0.031). CONCLUSIONS: The use of sugammadex, compared with pyridostigmine, showed a significantly reduced overall incidence of postoperative pulmonary complications and decreased duration of chest tube use and postoperative hospital stay in patients undergoing VATS lobectomy, suggesting that sugammadex might be helpful in improving clinical outcomes in such patients.
